Assess whether RWE can replace or only supplement an RCT (a675ff)

Situation

An FAERS cluster in a demographic the trials under-enrolled put advisory-committee question list that exposes a weak secondary endpoint in front of pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / Clinical and Evidence Strategy close is RWE can replace or from advisory-committee question list that exposes a weak secondary endpoint, and the live options are RWE can replace, Only supplement an RCT.

Decision

Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose RWE can replace / Only supplement an RCT using advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend RWE can replace from advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend RWE can replace from advisory-committee question list that exposes a weak secondary endpoint; Only supplement an RCT is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled.
• An FAERS cluster in a demographic the trials under-enrolled never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close RWE can replace or.
• Two facts in advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled conflict for pharmacovigilance medical reviewer; hold this Clinical and Evidence Strategy file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move RWE can replace or for pharmacovigilance medical reviewer.